ATE507295T1 - Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie - Google Patents

Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie

Info

Publication number
ATE507295T1
ATE507295T1 AT01920913T AT01920913T ATE507295T1 AT E507295 T1 ATE507295 T1 AT E507295T1 AT 01920913 T AT01920913 T AT 01920913T AT 01920913 T AT01920913 T AT 01920913T AT E507295 T1 ATE507295 T1 AT E507295T1
Authority
AT
Austria
Prior art keywords
compositions
methods
immunostimulatory
dendritic cell
based immunotherapy
Prior art date
Application number
AT01920913T
Other languages
English (en)
Inventor
Reiner Laus
Damir Vidovic
Thomas Graddis
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Application granted granted Critical
Publication of ATE507295T1 publication Critical patent/ATE507295T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01920913T 2000-03-30 2001-03-30 Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie ATE507295T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19350400P 2000-03-30 2000-03-30
PCT/US2001/010515 WO2001074855A2 (en) 2000-03-30 2001-03-30 Compositions and methods for dendritic cell-based immunotherapy

Publications (1)

Publication Number Publication Date
ATE507295T1 true ATE507295T1 (de) 2011-05-15

Family

ID=22713907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920913T ATE507295T1 (de) 2000-03-30 2001-03-30 Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie

Country Status (13)

Country Link
US (2) US7060279B2 (de)
EP (1) EP1272633B1 (de)
JP (1) JP5110674B2 (de)
AT (1) ATE507295T1 (de)
AU (2) AU4791901A (de)
CA (1) CA2403964C (de)
CY (1) CY1111718T1 (de)
DE (1) DE60144516D1 (de)
DK (1) DK1272633T3 (de)
ES (1) ES2362715T3 (de)
NZ (1) NZ522066A (de)
PT (1) PT1272633E (de)
WO (1) WO2001074855A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
US7413869B2 (en) * 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
WO2003087338A2 (en) * 2002-04-11 2003-10-23 Amgen, Inc. Her-2 receptor tyrosine kinase molecules and uses thereof
EP1601684B1 (de) * 2003-03-05 2014-10-15 Dendreon Corporation Zusammensetzungen und verfahren unter anwendung von polypeptiden mit alternativem leserahmen zur behandlung von krebs und infektionskrankheiten
US7737253B2 (en) * 2006-06-16 2010-06-15 Bresagen, Inc. Human cancer stem cell culture compositions comprising Erbb2 variants and methods of use thereof
US7972602B2 (en) * 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2008206463B2 (en) * 2007-01-15 2013-04-04 Glaxosmithkline Biologicals Sa Fusion proteins comprising the tumor rejection antigens NY-ESO-1 and LAGE-1
ES2398492T3 (es) * 2007-01-15 2013-03-19 Glaxosmithkline Biologicals Sa Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
US8309096B2 (en) 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
CA2682661C (en) * 2007-03-22 2017-03-14 Dendreon Corporation Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
CA2856329A1 (en) * 2011-11-17 2013-05-23 Glia Sp Z.O.O. Compositions and methods for treating glioma
EP2777711A1 (de) 2013-03-11 2014-09-17 Icon Genetics GmbH HER2/neu-Krebsimpfstoff
US11464839B2 (en) 2015-12-04 2022-10-11 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different MHC molecules
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2048981B (en) * 1979-05-23 1982-11-17 Coal Ind Equipment for laying a layer of elongate material adjacent to an exposed rock or mineral surface in an underground mine
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0692973A1 (de) * 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide beschichtete zellen als immunogene
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5586538A (en) * 1995-11-13 1996-12-24 Caterpillar Inc. Method of correcting engine maps based on engine temperature
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
CA2286477A1 (en) * 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
US6194152B1 (en) * 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
EP1141007B1 (de) * 1998-12-14 2013-05-15 Dendreon Corporation Zusammensetzungen und methoden zur steigerung der haupthistokompatibilitätskomplex klasse i abhängigen antigen-präsentierung
CZ20012587A3 (cs) * 1999-01-29 2002-05-15 Corixa Corporation Izolovaný protein, nukleová kyselina, virový vektor, farmaceutický prostředek, izolovaná populace T buněk, způsob posílení imunitní odpovědi, způsob odstranění nádorových buněk, způsob stimulace a/nebo namnoľení T buněk a způsob přípravy fúzního proteinu
PT1187629E (pt) * 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease

Also Published As

Publication number Publication date
WO2001074855A2 (en) 2001-10-11
WO2001074855A3 (en) 2002-03-07
ES2362715T3 (es) 2011-07-12
DK1272633T3 (da) 2011-05-23
CY1111718T1 (el) 2015-10-07
EP1272633B1 (de) 2011-04-27
CA2403964C (en) 2013-04-30
US20050232932A1 (en) 2005-10-20
EP1272633A2 (de) 2003-01-08
US20020061310A1 (en) 2002-05-23
PT1272633E (pt) 2011-06-27
CA2403964A1 (en) 2001-10-11
DE60144516D1 (de) 2011-06-09
AU4791901A (en) 2001-10-15
AU2001247919B2 (en) 2006-02-09
JP5110674B2 (ja) 2012-12-26
US7659117B2 (en) 2010-02-09
NZ522066A (en) 2004-08-27
US7060279B2 (en) 2006-06-13
JP2003529608A (ja) 2003-10-07

Similar Documents

Publication Publication Date Title
ATE507295T1 (de) Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie
DK0870022T3 (da) Immunstimulerende sammensætning og fremgangsmåde
Botarelli et al. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes
WO2001029233A3 (en) Chimeric immunogenic compositions and nucleic acids encoding them
WO1999006544A8 (en) Membrane-bound cytokine compositions and methods of modulating an immune response using same
ATE231917T1 (de) Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
CY1109649T1 (el) Αντιγονα και συνθεσεις απο neisseria
DK1280900T3 (da) Dendritcellespecifikke co-stimulerende molekyler
CA2290485A1 (en) Method for the production of non-immunogenic proteins
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
CY1109710T1 (el) Επιτοπα βοηθητικων τ λεμφοκυτταρων
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2004026238A8 (en) Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
AU2363301A (en) Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes
ATE389397T1 (de) Adjuvante zusammensetzungen
DK0996636T3 (da) HA-1-antigenet
ATE374244T1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
WO2003104263A3 (en) Cytokines and cytokine receptors with reduced immunogenicity
DE69426303D1 (de) Verfahren zur unterdrückung der immunantwort durch gentherapie
WO2004020592A3 (en) Retroductal salivary gland genetic vaccination
ATE346926T1 (de) Menschliche twik-8 moleküle und ihre verwendung
ATE416253T1 (de) Atcr-1, eine humane acyltransferase und verwendungen davon
WO2002088357A3 (en) 84242, 8035, 55304, 52999, and 21999, novel human proteins and methods of use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272633

Country of ref document: EP